Skip to main content
Premium Trial:

Request an Annual Quote

Sensium Technologies Expands License to Protein Biochip Technology

NEW YORK, July 26 – Sensium Technologies has expanded its license to protein biochip technology from the University of Alberta and Canadian technology transfer company PENCE, Sensium said Thursday.

Sensium, the proteomics subsidiary of Aurora, Ontario-based biopharmaceutical company Helix BioPharma, will now be able to use the technology exclusively in drug discovery, as well as in other applications. The original license dates from 1996.

Known as heterodimer protein technology, the intellectual property in the license covers the capture and detection of proteins binding to a surface. Sensium is using the technology, along with separate molecular sensing technology, in protein biochips and other tools to discover and develop diagnostics and pharmaceuticals.

Helix BioPharma is the majority owner of Sensium, with outside investors holding 24 percent of its stock. Sensium’s board of directors includes Paul Russo, CEO of Genesis Microchip, and Robert Hodges, a Univerisity of Alberta Researcher and CEO of PENCE.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.